anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients admitted to dermatology clinics, with moderate to severe psoriasis for whom the physician has decided to initiate psoriasis treatment with anti-TNFs in accordance with Turkish Ministry of Health regulations and reimbursements. (Tumor necrosis factor inhibitors can be used for the treatment of moderate to severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or Psoralen Ultra-Violet A. Patients should be screened for latent tuberculosis and appropriate anti-tuberculosis prophylaxis must be initiated if latent tuberculosis is diagnosed). This is a national, multi-center, observational, prospective photographic atlas study in patients who are treated with tumor necrosis factor inhibitors for moderate to severe psoriasis in daily clinic according to Turkish regulations and reimbursement. Demographic data will be collected by the investigator at the beginning of the study. Every participant will be examined by the investigator and the Psoriasis Area Severity Index will be determined at the beginning of the study and at weeks 4, 8, 16 and 24. Each patient will be asked to fill out the Dermatology Life Quality Index at each visit. Each patient will be asked to fill out the Work Productivity and Activity Impairment Questionnaire: Psoriasis at the beginning and last visit (week 24). A standardized set of photographs will be taken at the beginning of the study and at weeks 4, 8, 16 and 24 by a dermatologist trained about standardized photograph positioning and settings. Psoriasis Area Severity Index, Dermatology Life Quality Index and Photographic scores will be statistically analyzed separately in order to evaluate treatment response.
Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin, their derivatives and analogues are known as inhibitors of HMG-CoA reductase and are used as antihypercholesterolemica. Most of them are produced by fermentation with various kinds of microorganisms belonging to the species of Aspergillus, Monascus, Nocardia, Amycolatopsis, Mucor or Penicillium, but some of them are the result of treatment of fermentation products according to the methods of chemical synthesis or products of total chemical synthesis respectively. The above mentioned active substances may be destabilized by numerous exterior factors such as light, heat and pH. Besides, their degradation can be enhanced by interactions with other pharmaceutical ingredients such as fillers, binders, lubricants, slip agents and degradation agents. Therefore, pharmaceutical ingredients and the procedure of a pharmaceutical formulation preparation shall be carefully selected to avoid the above mentioned undesirable interactions and reactions. The submitted invention refers to a stable pharmaceutical formulation intended for healing hypercholesterolemia and hyperlipidemia. More precisely, the subject of invention is a new stable solid pharmaceutical formulation containing the inhibitor of the HMG-CoA reductase as active substance, for example atorvastatin, pravastatin, fluvastatin, and cervastatin or their pharmaceutically acceptable salts.
PURPOSE:To improve accuracy of a casting and to reduce the production post by containing the specific wt. of magnesium oxide powder and/or aluminum oxide powder having the specific grain sizes. CONSTITUTION:Molding material is formed by the magnesium oxide and aluminum oxide powders having <=100mum the grain sizes and regulating >=10wt.% the component composition, respectively. This molding material is kneaded with water and heated, dried and hardened, and then, the magnesium oxide and the aluminum oxide having <=100mum the grain sizes become magnesium hydroxide and aluminum hydroxide, respectively, and the molding material is expanded at a little quantity. Next, at the time of executing the pouring of molten metal into the mold forming spinel compound during sintering, as cooling shrinkage of the casting material coincides with expansion of the cavity, the accuracy of the casting is obtd. as desirable. As the cost of the molding material is low, the accuracy of the casting is improved and the production cost is reduced.
The plant extract contains active substances of the alcohol extract from Rudus sp. diversa, Cynodon dactylon (L.), Melissa officinalis L., Collendula officinalis L., Hypericum perforatum L., Plantago major L., Capsella bursa pastoris (L.) Medic., Achillea millefolium L., Equisetum arvence l. Crataegus monogyna Jacq., Morrus alba L.p. The main point of the method is that the previously finely cut and screened plants are wetted with water, placed in a metal vessel macerator after which 50% solution of ethyl alcohol is poured over them. The mixture is agitated several times daily by an agitator of Morrus alba, L., resting in the metal macerator vessel for 15 days. The obtained liquid is poured out, the remaining mixture is pressed, and the obtained after pressing liquid is mixed with the one poured out before. The drink is a mixture of the plants extract containing the above mentioned active substances and 50% ethyl alcohol solution.
A purified protein kalinin is disclosed that provides adhesion between epidermal keratinocytes and the underlying dermis. Purified kalinin localizes to the anchoring filaments of basement membranes of human subepithelial skin, trachea, esophagus, cornea and amnion when exposed to monoclonal antibody BM165. The protein has a molecular weight of approximately 400-440kDa and separates on Western blots into fragments of 165kDa, 155kDa, 130kDa and 105kDa when its disulfide bonds are reduced. The epitope of BM 165 is identified on the 165kDa fragment when the blots are probed with BM165. The protein has a rotary shadow image which reveals an asymmetric 170nm long rod having two globules at a first end and a single globule at a second end of the rod. A method is also disclosed for improving adhesion of transplanted keratinocytes to an underlying sub-strate, such as the human dermis, by optimizing the production of kalinin from cultured keratinocytes, or providing an exogenous source of kalinin between the keratinocytes and substrate.
Devices, kits and methods for reducing the risk of infection at an injection or incision site are described herein. The device contains a bioadhesive, biocompatible and bioerodable material and one or more disinfectant agents. In the preferred embodiment, the material is formed of one ore more hydrogels Optionally, the device also contains one or more anesthetics to decrease discomfort. The device may be marked or calibrated to facilitate localized injection or incision at a pre-specified site on the skin or mucus membrane. After identifying or selecting the injection or incision site, the device is placed on the site for a time sufficient to achieve localized disinfection, and optionally localized anesthesia. Then the needle or surgical instrument is inserted through the composition into the site. Thereafter, the drug is administered, fluid is removed, in the case of an injection, or the surgical instrument is placed at the site, in the case of an incision. Then the needle or surgical instrument is removed from the site, and the device forms a continuous seal over the site. The disinfectant and/or anesthetic is delivered before, during, and/or after the treatment. Optionally, the disinfectant and/or anesthetic is released in a controlled-release manner. Optionally, the disinfectant and/or anesthetic may de delivered following a time-delay. In a second embodiment, the device may be placed at a site following the injection or incision at the site to reduce the risk of infection, provide anesthesia, and/or prevent reflux of blood or fluid following the injection or incision.
Chronic lower back pain has a profound impact on a patient's life and body. These patients face a litany of internal and external stressors. These stressors cause a detrimental sustained activation of the endogenous stress response, which is mediated by the autonomic nervous system. Our central hypothesis is that this high stress load exacerbates the symptoms of chronic pain by causing changes in how the brain processes pain signals from the periphery. If researchers can better understand how stress plays a role in the mitigation of pain, then there may be improvements in patient's quality of life. Restricted Environmental Stimulation Therapy (REST) flotation has been identified as a possible alternative treatment to pharmacological intervention for several conditions like generalized anxiety disorder by helping to reduce stress. However, there have yet to be any investigation into what affects that REST flotation has in chronic lower back pain.
Methods and compositions are provided for inhibiting, preventing and treating amyloid depositions, e.g. in pancreatic islets, wherein the amyloidotic deposits are islet amyloid polypeptide (IAPP)-associated amyloid deposition or deposits. Accordingly, the compositions and method of the invention are useful for inhibiting diabetes. The invention also provides a process for the preparation of cells suitable for transplantation into a mammal, which cells are capable of forming fibrils, said process comprising contacting the cells with an inhibitor of fibril formation. In particular the process prepares cells for use in a method of treating diabetes. Also provided are a culture medium comprising the inhibitor more particularly selected from the group consisting of 3-(3-hydroxy-1-propy)amino-1-propanesulfonic acid; DL-2-amino-5-phosphovaleric acid; 4-Phenyl-1-(3'-sulfopropyl)-1,2,3,6-tetrahydropyridine, cyclohexylsulfamic acid, O-phospho-L-serine, hexafluoroglutaric acid, 8-methoxyquinoline-5-sulfonic acid, 3-amino-2hydroxy-1-propanesulfonic acid, and 3-dimethylamino-1-propanesulfonic acid and 1,2,3,4-tetrahydroisoquinoleine.
BACKGROUND: The number of operations concerning revision arthroplasty has been increasing continuously in recent years, and it can be assumed that they will continue to increase in the future. If an arthroplasty implant becomes loose, it must be changed. The question often arises as to how the new implant should be fixed in the bone.
ADVANTAGES: Revision implants can be inserted into the bone without cement. In the subsequent period, a secondary osseointegration of the implant takes place. Another possibility is to anchor the implant by using bone cement. The advantage of cemented anchorage is that the implant is firmly fixed in the bone, in principle, immediately, and it is possible to fully load the implant directly. Direct postoperative full weight bearing is helpful, especially for older and multimorbid patients, in order to achieve rapid mobilization.
PREREQUISITES AND CHALLENGES: When using cement in revision cases, however, there are a few prerequisites and challenges that the surgeon should definitely take into account. In the case of revision, the bone in the former implant bed is often deficient and appears thinned and sclerosed. It is, therefore, important to analyze the bone quality preoperatively on radiographic images and to include it in the planning of the anchoring strategy. In addition, the individual bone quality of the patient must also be taken into account intraoperatively. In any case, it must be clarified whether the basic prerequisites for the sufficient bond strength of the cement with the bone to be formed can still be met. Furthermore, the principles of cementing technique must be strictly observed, and the goal of a perfect cement mantle must be aimed for. If the indication for this is overstated, early loosening of the cemented revision arthroplasty is very likely.
The ROAM-DBS study is a prospective, multi-center, randomized control, open-label, post-market cohort study intended to gather clinical data on the effect of the NeuroSphere Virtual Clinic feature (remote care) on the time needed to optimize DBS stimulation parameters after implant. The study will enroll up to 100 subjects from up to 15 centers in geographies where Abbott DBS systems with the Virtual Clinic feature are approved, which may include North America, and Europe. Subjects should be participants in the ADROIT study (NCT04071847). Subjects will be followed to a 3 month visit where the primary endpoint will be assessed. Subjects will be further followed for 1 year for final data assessment. Subjects will remain enrolled in ADROIT after the end of the ROAM study, and will complete the ADROIT 6 month and 1 year visits under that protocol. The study is expected to enroll subjects for up to 2 years, and complete all follow-up visits within 3 years.
NEW MATERIAL:A vitamin C clathrate compound composed of vitamin C and a compound having a bridge-head nitrogen atom. USE:Useful as a component for pharmaceuticals, health foods, antioxidants, additives and cosmetics. It improves the stability of vitamin C and exhibits excellent warmth-retaining effect. PREPARATION:For example, each of vitamin C and a compound having a bridge-head nitrogen atom [e.g. a strychnin of formula (R is H)] is dissolved in methanol, the solutions are mixed together and the obtained mixed solution is concentrated in nitrogen atmosphere under reduced pressure to obtain the objective vitamin C clathrate compound. Examples of the compound having bridge-head nitrogen atom are brucin, cinchonidine, cinchonamine, cinchonine, quinidine, quinine, quinuclidine, quinine ethyl carbonate, triethylenediamine, hexamethylenetetramine, 1,8-diazabicyclo[5,4,0]-7-undecene, etc., in addition to strychnin.
Participants receive a pembrolizumab 200 mg intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment PLUS BSC. Participants who complete 35 administrations or achieve a complete response (CR) but progress after discontinuation can initiate a second course of pembrolizumab for up to 17 cycles (approximately 1 additional year).
The first dosing cohort received 5 mg/kg/dose oral every 8 hours for 7 days (21 doses) of a 40 mg/mL oral liquid formulation. Subsequent dosing cohorts are receiving 8.5 mg/kg/dose oral every 8 hours for 7 days (21 doses) of a 40 mg/mL oral suspension formulation.
Participants will be recruited based on the Early Life Plan Project, an ongoing hospital-based prospective birth cohort study. Pregnant women will be recruited at the time of booking for prenatal care. The sleep patterns of pregnant women will be assessed at 12-16 weeks of gestation using the Pittsburgh Sleep Quality Index (PSQI) questionnaire. Women with a PSQI score greater than 5 and who self-report as not being habitual nappers in the last 3 months will be recruited. These women will receive lifestyle recommendations to nap regularly for 15-30 minutes between 12:00 and 15:00. Whether they adopt this lifestyle change or the actual duration of their naps will be entirely up to the participants. An Actiwatch will be given to the participants during early pregnancy (12-14 weeks), mid-pregnancy (22-24 weeks), and late pregnancy (29-32 weeks). Instructions will be included on how to wear the watch, with participants advised to wear it on the non-dominant wrist continuously for 7 days, except when swimming or bathing. In addition to the Actiwatch, participants will complete a sleep questionnaire during early pregnancy (12-14 weeks), mid-pregnancy (26-27 weeks), and late pregnancy (35-37 weeks) to subjectively assess their nighttime sleep and napping over the past month. The neurodevelopment of the participants' offspring will be followed up and assessed using the Bayley Scales of Infant and Toddler Development at 6 months, 12 months, 18 months, and 2 years of age.
OBJECTIVE: To investigate the treatment plan and prognosis of children with ocular dyskinesia and hemifacial spasm secondary to pontine tumours adjacent to the fourth ventricle.
METHODS: In this retrospective study, the clinical information of 10 consecutively collected children with ocular dyskinesia and hemifacial spasm secondary to pontine tumours adjacent to the fourth ventricle was analyzed. All 10 children underwent pontine tumour resection through a trans-cerebellomedullary fissure approach; 4 children underwent preoperative diffusion tensor imaging scans to determine the relationship between the tumour and facial nerve nucleus, and the other 6 children underwent intraoperative deep electroencephalography (EEG) tumour monitoring, in which the tumour electrical discharge activity of the tumour was recorded. A voxel distribution map was established to describe the distribution of the tumour location, and patient prognosis was evaluated through clinical and imaging follow-up.
RESULTS: All 10 children achieved total tumour resection; 9 tumours were pathologically suggested to be ganglioglioma (WHO grade I), and 1 was a hamartoma. The symptoms of the original ocular dyskinesia and hemifacial spasm disappeared immediately after the operation. The children were followed up for 4-75 months, and none of the symptoms recurred; four cases with preoperative diffusion tensor imaging showed that the tumour was close to the facial nerve. Four in six intraoperative electrophysiological monitoring showed that the tumour had electrical discharge behaviour, and the tumour distribution map indicates a high density of tumour presence in the facial nerve nucleus and the nucleus of the abducens nerve.
CONCLUSIONS: In paediatric patients, the facial symptoms are related to the location and abnormal electrical discharge of the tumour. There is no significant correlation between ocular dyskinesia and the location of the tumour. Conventional antiepileptic therapy for this disease is ineffective, and early surgical intervention for total tumour resection can achieve a clinical curative effect.
Detection of high glycated hemoglobin (A1c) is associated with worse postoperative outcomes, including predisposition to develop systemic and local infectious events. Diabetes and infectious Outcomes in Cardiac Surgery (DOCS) study is a retrospective case-control study aimed to assess in DM and non-DM cardiac surgery patients if a new screening and management model, consisting of systematic A1c evaluation followed by a specialized DM consult, could reduce perioperative infections and 30-days mortality. Effective July 2021, all patients admitted to the cardiac surgery of IRCCS ISMETT were tested for A1c. According to the new protocol, glucose values of patients with A1c ≥ 6% or with known diabetes were monitored. The diabetes team was activated to manage therapy daily until discharge or provide indications for the diagnostic-therapeutic process. Propensity score was used to match 573 patients managed according to the new protocol (the Screen+ Group) to 573 patients admitted before July 2021 and subjected to the traditional management (Screen-). Perioperative prevalence of infections from any cause, including surgical wound infections (SWI), was significantly lower in the Screen+ as compared with the Screen- matched patients (66 [11%] vs. 103 [18%] p = 0.003). No significant difference was observed in 30-day mortality. A1c analysis identified undiagnosed DM in 12% of patients without known metabolic conditions. In a population of patients undergoing cardiac surgery, systematic A1c evaluation at admission followed by specialist DM management reduces perioperative infectious complications, including SWI. Furthermore, A1c screening for patients undergoing cardiac surgery unmasks unknown DM and enhances risk stratification.
The invention relates to the food industry and to bioengineering, in particular to a method for producing from mushrooms a biologically active product exhibiting a hepatoprotective action. The inventive method for producing an biologically active product is based on the cultivation of a mushroom of Fusarium sambucinum specie on a nutrient medium comprising 3-4 % of carbon source, 0.2-0.3 % nitrogen, and 0.07-0.08 % of microelements. Said method consists in carrying out a sterile cultivation with a temperature ranging from 26 to 30 °C by steering and aerating for 48-72 hours, in subsequently separating a biomass and in obtaining a cultural fluid. Prior to cultivation, a seed material is prepared by pre-cultivating a Fusarium sambucinum specie mushroom in the presence of ethanol. During cultivation, 0.5-1.5 % of ethanol is added into the nutrient medium in the form of a metabolite production enhancing factor. Said invention makes it possible to obtain a novel biologically active product in the form of a cultural fluid, which is enriched with biologically active components (metabolites) and exhibits a pronounced hepatoprotective action.
Dosage of thiothixene capsules should be individually adjusted depending on the chronicity and severity of the symptoms of schizophrenia. In general, small doses should be used initially and gradually increased to the optimal effective level, based on patient response.

Some patients have been successfully maintained on once-a-day thiothixene therapy.

The use of thiothixene capsules in children under 12 years of age is not recommended because safe conditions for its use have not been established.

In milder conditions, an initial dose of 2 mg three times daily is recommended. If indicated, a subsequent increase to 15 mg/day total daily dose is often effective.

In more severe conditions, an initial dose of 5 mg twice daily is recommended.

The usual optimal dose is 20 to 30 mg daily. If indicated, an increase to 60 mg/day total daily dose is often effective. Exceeding a total daily dose of 60 mg rarely increases the beneficial response.
The active comparator group will undergo the same interventions as the experimental group with the addition of conventional strength training including the same program as the experimental group but without blood flow restriction of any kind: the weight of the dumbbell should be between 20-40% of their 1 rep max. The exercises were targeting the extensor muscles, applied by extending the wrist while holding the dumbbell for 4 sets (35 repetitions, 15 repetitions,15 repetitions,15 repetitions) respectively, and exercises targeting the supinator's and pronators while the participants were holding the dumbbell with forearm in neutral position, and were asked to supinate or pronate their forearm.
PURPOSE:To provide a cosmetic favorable in the adherability to the skin, causing little makeup spoilage, and also good to touch. CONSTITUTION:The objective cosmetic can be obtained by formulating, as the essential ingredients, (A) pref. 0.01-40 (esp. 1-20)wt.% of polymethylsilsesquioxane powder, pref. spherical in the particle shape, 0.1-20mum (esp. 2-12mum) in means particle size, more pref. with the particle size distribution falling within + or -30% of the mean size and (B) 0.01-95wt.% of hydrophobicized powder pref. 0.01-80 (esp. 0.05-20)mum in particle size in (C) a makeup cosmetic such as foundation, eye shadow or cheek rouge or (D) base cosmetic such as milky lotion or cream. With the present cosmetic having the above-mentioned effects, such problems resulting from using hydrophobicized powder causing poor touch feeling and bad spreadability will be resolved at a stroke.
The present invention provides compositions and methods for modulating leukocyte activation. Nucleic acids and proteins which are capable of modulating leukocyte activation are provided. Compositions and methods for the treatment of disorders related to leukocyte dysfunction or dysregulation are also provided. Prophylactics and methods for the prevention of such disorders are also provided. Also provided are compositions and methods for diagnostic and prognostic determination of such disorders. Further provided are assays for the identification of bioactive agents capable of modulating leukocyte activation.
Cohort A: For patients that have indication for systemic therapy with standard chemotherapy. This cohort has a phase II design; the Objective Response Rate (ORR) will be evaluated according to the RECIST criteria (version 1.1) after 2 and 3 cycles of PIPAC with Cisplatin (7.5 mg/m²) + Doxorubicin (1.5 mg/m2 ) or Oxaliplatin (92 mg/m2) according to the primary cancer, in association with standard systemic chemotherapy.